Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. (EVGN) is a computational biology and chemistry company that regularly publishes news about its AI‑driven platforms, collaborations and corporate developments. The EVGN news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Evogene applies big data and artificial intelligence to life‑science product discovery in pharmaceuticals and agriculture.
Recent announcements highlight Evogene’s focus on ChemPass AI, its generative AI tech‑engine for small‑molecule design and optimization. News items include the completion of a generative AI foundation model for small‑molecule design developed with Google Cloud, as well as updates on how ChemPass AI is being positioned as the core engine for the company’s pharma and agricultural activities.
Evogene’s news also covers scientific collaborations, such as agreements with Unravel Biosciences to design small‑molecule therapeutics for demyelinating diseases and with a Tel Aviv University research group to develop small molecules targeting metabolite self‑assembly in metabolic diseases. In agriculture, readers can find updates related to subsidiaries like Casterra Ag, including partnerships to advance mechanized castor farming for bio‑based industries.
In addition, the EVGN news stream features financial and corporate communications, including quarterly results, conference call schedules, investor conference presentations, restructuring steps and transactions such as the sale of most of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL. Investors and observers can use this page to monitor how Evogene’s strategy, partnerships and technology platforms evolve over time.
Evogene (Nasdaq: EVGN) entered a warrant inducement agreement with an existing institutional investor to generate approximately $3.4 million of gross proceeds. The investor will immediately exercise August 2024 Series A and B warrants at $1.00 per share.
In return, the investor receives privately placed Series A-1 and B-1 warrants to buy up to 2,538,462 shares each at an exercise price of $1.25; A-1 expires in five years and B-1 in 18 months. Closing is expected on or about February 11, 2026, subject to customary conditions.
Evogene (NASDAQ: EVGN) announced on February 10, 2026 an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform using Google Cloud Vertex AI. The phase aims to accelerate and scale small-molecule discovery, shorten design–make–test–analyze cycles, and enable parallel molecular exploration.
The move follows a prior October 2024 milestone that built a generative AI foundation model now core to ChemPass AI™. Evogene said the partnership could broaden offerings, improve speed and cost structure, and make some tools available via Google Cloud Marketplace.
Evogene (NASDAQ: EVGN) appointed Prof. John J. Irwin (UCSF) and Prof. Dan T. Major (Bar-Ilan) to its Scientific Advisory Board on February 9, 2026.
The appointments are intended to strengthen scientific leadership for ChemPass AI™, Evogene's proprietary generative AI engine for small-molecule discovery across pharmaceutical and ag-chemical programs.
Evogene (NASDAQ: EVGN) subsidiary Biomica granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license to BMC128 (LS-LBP-002), a live four-strain microbiome-based therapeutic showing early Phase 1 clinical promise in renal cell carcinoma and non-small cell lung cancer.
BMC128 displayed an excellent safety profile and early signs of efficacy, including disease stabilization in patients with prior progression. Under the deal, Lishan Biotech will lead global development, manufacturing, and commercialization; Biomica is eligible for development milestones and future royalties. Lishan plans Phase 2 studies and regulatory filings in China and the United States.
Evogene (NASDAQ: EVGN) and Unravel Biosciences announced a collaboration on January 7, 2026 to discover and optimize a first-in-class small-molecule therapy aimed at restoring myelin and reversing neurological damage in demyelinating disorders including multiple sclerosis.
The program combines Evogene's ChemPass AI generative chemistry platform with Unravel's BioNAV predictive biology and Living Molecular Twins patient-derived data to design brain-penetrant inhibitors against a novel demyelination target discovered by Unravel. Work will use in vitro, in vivo, and in silico outcome simulation to advance lead candidates toward potential clinical development.
Evogene (Nasdaq: EVGN) appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceutical and AI-enabled drug discovery and holds a PhD plus postdoctoral research in biochemistry and proteomics from the Weizmann Institute of Science.
Her prior roles include CEO and Co‑Founder of Protica Bio and senior R&D and management positions at EcoPhage, BiomX and Teva. Management says she will help scale Evogene's small‑molecule discovery and optimization powered by the ChemPass AI platform and expand industry collaborations.
Casterra and Fantini announced a strategic collaboration on November 11, 2025 to develop integrated, mechanized solutions for large-scale commercial castor farming.
The partnership pairs Casterra's proprietary high-yield castor varieties with Fantini's precision harvesting and threshing machinery to enable scalable production of castor oil feedstock for biofuels and bio-based products. The release cites a global castor oil market valued at USD 2.4 billion, projected to reach USD 3.09 billion by 2030 at a 5.20% CAGR. Fantini estimates its solutions can cut carbon footprint by about two-thirds versus widely used alternatives.
Evogene (NASDAQ: EVGN) will release its third quarter 2025 financial results on Thursday, November 20, 2025. Company management will host a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time) to discuss the results. Investors must register in advance to attend: https://www.veidan-conferencing.com/evogene. The full conference will be available on the company website a few days after the call.
Evogene (NASDAQ: EVGN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Ofer Haviv will present on September 10, 2025, at 1:00 PM ET, focusing on the company's strategic shift towards maximizing value from its ChemPass AI technology for small molecule discovery in pharmaceutical and agricultural applications.
The presentation will showcase the company's proprietary generative AI tech-engine capabilities. One-on-one meetings with management will be available for interested investors and companies attending the conference.
Evogene (NASDAQ: EVGN) reported Q2 2025 financial results, highlighting its strategic transformation focused on ChemPass AI, its platform for AI-driven small molecule discovery. The company reported H1 2025 revenues of $3.2 million, up from $2.3 million in H1 2024, while reducing operating expenses to $7.7 million from $11.1 million year-over-year.
Key developments include the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL for $18.71 million, completion of a major restructuring with a 30% workforce reduction at Evogene and 40% at AgPlenus, and raising $4.4 million through ATM facility. The company's cash position stood at $11.7 million as of June 30, 2025, with an 18-month operational runway post-ICL transaction.
FAQ
What is the current stock price of Evogene (EVGN)?
What is the market cap of Evogene (EVGN)?
